Investor Presentation Q1-Q3 2020

25 Investor presentation First nine months of 2020 Sales growth of 7% at CER, driven by IO sales growth of 12% and 2% sales growth in NAO Historic sales by geography Novo Nordisk® Reported sales for the first nine months 2020 Reported sales and growth breakdown for the first nine months 2020 8% 9% ROW 9% 11% Region 32% 31% China 11% 14% 51% 50% 28% EMEA 2015 North America EMEA 2019 China ROW North America Operations Regions Sales (MDKK) Growth Share of growth International Operations 50,399 12% 83% EMEA 26,159 11% 39% Region China 10,836 12% 19% 47% ROW 13,404 13% 25% North America Operations 44,409 2% 17% Here of USA 41,947 2% 11% Total sales 94,808 7% 100% Sales of DKK 94.8 billion (+7%) IO: International Operations; NAO: North American Operations; EMEA: Europe, Middle East, and Africa; Row: Rest of World; Region China covers mainland China, Hong Kong and Taiwan. Note: Numbers do not add up to 100% due to rounding; Growth at Constant exchange rates Note: Sales numbers are reported in Danish kroner; Growth is at constant exchange rates

View entire presentation